![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.prnewswire.com/news-releases/pantherx-rare-selected-by-ucb-as-the-exclusive-specialty-pharmacy-for-zilbrysq-zilucoplan-for-the-treatment-of-generalized-myasthenia-gravis-gmg-in-adult-patients-who-are-anti-acetylcholine-receptor-achr-antibody-positive-302031436.html
https://www.prnewswire.com/news-releases/zilbrysq-zilucoplan-is-now-commercially-available-in-the-us-for-the-treatment-of-generalized-myasthenia-gravis-gmg-in-adult-patients-who-are-anti-acetylcholine-receptor-achr-antibody-positive-302025019.html
https://www.prnewswire.com/news-releases/ucb-announces-us-fda-approval-of-zilbrysq-zilucoplan-for-the-treatment-of-adults-with-generalized-myasthenia-gravis-301959745.html
https://www.prnewswire.com/news-releases/ucb-announces-us-fda-acceptance-of-new-drug-application-and-ema-maa-validation-for-zilucoplan-for-the-treatment-of-generalized-myasthenia-gravis-in-adult-patients-301676223.html
https://endpts.com/ucb-details-positive-pivotal-data-for-myasthenia-gravis-days-after-astrazeneca-scores-ok-for-soliris-successor/
http://www.pharmafile.com/news/607493/first-promising-innovative-medicine-designation-self-administered-treatment-rare-disease
https://www.prnewswire.com/news-releases/ucb-announces-positive-data-in-myasthenia-gravis-with-zilucoplan-phase-3-study-results-301475451.html
https://www.theguardian.com/world/2020/jun/01/uk-hospitals-trial-five-new-drugs-search-coronavirus-treatment
https://www.businesswire.com/news/home/20190409005394/en/Ra-Pharmaceuticals-Announces-Completion-End-of-Phase-2-Interactions/?feedref=JjAwJuNHiystnCoBq_hl-bQQCakZDujohEJegUyaJwquReQ0P23MrIoWkrUSV24ZevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxbNWfZlBntHS6jpH5ROLXsTFMkl05DM8ABqeyBleEmzJA==